Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan.
Yoshida C, Fletcher L, Ohashi K, Wakita H, Kumagai T, Shiseki M, Matsuei K, Inokuchi K, Hatta Y, Shirasugi Y, Yamaguchi T, Sakamoto J, Branford S, Sakamaki H. Yoshida C, et al. Among authors: branford s. Int J Clin Oncol. 2012 Dec;17(6):584-9. doi: 10.1007/s10147-011-0328-x. Epub 2011 Oct 12. Int J Clin Oncol. 2012. PMID: 21986632
Molecular monitoring of chronic myeloid leukemia.
Hughes T, Branford S. Hughes T, et al. Among authors: branford s. Semin Hematol. 2003 Apr;40(2 Suppl 2):62-8. doi: 10.1053/shem.2003.50044. Semin Hematol. 2003. PMID: 12783378 Review.
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.
Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, Hughes T. Branford S, et al. Blood. 2008 Oct 15;112(8):3330-8. doi: 10.1182/blood-2008-04-150680. Epub 2008 Aug 6. Blood. 2008. PMID: 18684859 Free article.
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Hughes T, et al. Among authors: branford s. J Clin Oncol. 2009 Sep 1;27(25):4204-10. doi: 10.1200/JCO.2009.21.8230. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652056 Free PMC article. Clinical Trial.
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC. Branford S, et al. J Clin Oncol. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109697 Free PMC article. Clinical Trial.
156 results